Abstract 335P
Background
Neoadjuvant chemotherapy (NAC) of newly diagnosed breast cancer is used to improve resectability, reduce the extent of breast and axillary surgery and improve overall survival. Accurate assessment of locoregional response to NAC is important for surgical planning. Radiological method of choice is post-treatment breast magnetic resonance imaging (MRI), which determines the rate of response according to RECIST criteria. The primary indicator of outcome of NAC is pathologic complete response (pCR). This study aimed to compare radiologic and pathologic complete response rates after neoadjuvant treatment of early breast cancer.
Methods
A retrospective study of 259 breast cancer cases who received NAC between 01.01.2020 and 31.12.2021 at University Hospital Centre Zagreb was conducted with prior Ethics Committee approval. Radiological and pathohistological characteristics of the tumor at the time of diagnosis and after neoadjuvant treatment were analyzed using the Hospital information system (BIS). Furthermore, post-neoadjuvant therapy MRI findings were correlated with the postoperative pathohistological findings. Sensitivity, specificity, accuracy, and positive predictive value of radiologic complete response (rCR) as a predictor of pCR were calculated.
Results
Complete data was available for 94.98% (246/259) of patients. In 62 (25.20%) patients, rCR was recorded, radiologic partial response (rPR) in 150 (60.98%), stable disease in 22 (8.94%), and progressive disease in 9 patients. In 78 (31.71%) patients pCR was achieved, 46 (58.97%) were also classified as rCR, while 32 (41.03%) of those showed a radiological stable disease or rPR. Out of the 62 patients with rCR, 16 (25.81%) did not achieve pCR. The sensitivity and specificity of rCR were 90.48% and 58.97%, respectively, while positive predictive value was 82.61%. The overall accuracy of breast MRI in predicting pCR was 80.49%.
Conclusions
Although the sensitivity of breast MRI in predicting pCR was high, the specificity was low with only moderate overall accuracy. Low specificity can lead to an incorrect choice of breast surgery, therefore a better method of evaluation is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Krizic, N. Dedic Plavetic, T. Silovski: Financial Interests, Personal, Research Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
323P - Macrophage population analysis of the breast cancer microenvironment within the context of seroma formation after mastectomy (SerMa pilot study)
Presenter: Felicitas Schneider
Session: Poster session 02
325P - Impact of breast tumour location on axillary nodal involvement, chemotherapy use, and survival
Presenter: Yang Xu
Session: Poster session 02
326P - Sentinel lymph node mapping in breast cancer: Evaluating the dual-tracer method with indocyanine green and radioisotope
Presenter: Ava Kwong
Session: Poster session 02
328P - Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique
Presenter: Vanessa Petry
Session: Poster session 02
329P - Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy
Presenter: Jarle Karlsen
Session: Poster session 02
330P - Effect of radiotherapy in deep inspiration in patients with left breast cancer: Does the size of the target area affect the dose for the most crucial organs at risk?
Presenter: Zoltan Locsei
Session: Poster session 02
331P - miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ
Presenter: Tanja Marinko
Session: Poster session 02
332P - Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study
Presenter: Wei Li
Session: Poster session 02